Trend
DailyDowntrend (starting)
4 hourDescending Triangle
1 hourLeaning Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns up above $64.78
Key levels
Resistance$41.68
Resistance$41.00
Latest news & SEC filings
EarningsAN2 Therapeutics Posts Q3 2026 Results
EarningsAN2 Therapeutics reports Q3 EPS of $(0.17), beating $(0.20) estimate
SEC FilingAN2 Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All ANTX news →AN2 Therapeutics is a drug developer that uses boron-based chemistry to create small-molecule treatments. Its main candidate, epetraborole, is being studied for polycythemia vera and a type of nontuberculous mycobacterial lung infection, while AN2-502998 targets Chagas disease. Earlier-stage work covers cancer targets such as PI3Kα and ENPP1, plus infectious diseases like melioidosis and tuberculosis supported by grant funding. The company outsources manufacturing and has partners covering parts of Asia.
Based on the company's 10-K filed Mar 17, 2026.
Nasdaq · Healthcare
SEPT Low Target
$9.00
SEPT Mid Target
$9.00
SEPT High Target
$9.00
Analyst Consensus
$9.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ANTX.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$7.79
12
Moat Score
NONE
1/9
Piotroski Score
1.6
Altman Z-Score
Insider Signal
SELLING
1 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Eizen Joshua M | officer | Sale | 2,826 | $12K | Nov 5, 2026 |
| Readnour Robin Shane | director | Sale | 523 | $3K | Sep 9, 2026 |
| Readnour Robin Shane | director | Sale | 585 | $4K | Sep 9, 2026 |
| FitzPatrick Margaret M | director | Buy | 2,098 | $12K | Sep 1, 2026 |
| Williams Sarah Joanne | officer | Sale | 265 | $1K | May 29, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
32.56%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for ANTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:11:14 | $4.50 | 1,100 | $$5K | MIDPOINT |
| 20:10:11 | $4.46 | 1,100 | $$5K | BUY |
| 19:59:37 | $4.51 | 1,516 | $$7K | BUY |
| 19:35:58 | $4.60 | 1,700 | $$8K | SELL |
| 18:39:11 | $4.64 | 2,500 | $$12K | SELL |
5 dark pool trades shown · $$36K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for ANTX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $5 | Nov 20 | 9 | $$2000 | 100 | BLOCK |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for AN2 Therapeutics, Inc. (ANTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AN2 Therapeutics, Inc. (ANTX) is at $4.46, up 3.00% (+$0.13) at the Nov 11, 2026 close.
Latest ANTX news — Nov 10, 2026: AN2 Therapeutics Posts Q3 2026 Results · Nov 9, 2026: AN2 Therapeutics reports Q3 EPS of $(0.17), beating $(0.20) estimate
The average analyst price target for ANTX is $9.00, ranging from $9 to $9, based on 2 analysts. Latest: Guggenheim initiates on Jul 20, 2026.
Analyst ratings for ANTX: 1 Buy, 1 Hold, 0 Sell — consensus Hold.
ANTX last reported on Aug 11, 2026: EPS -$0.18 vs -$0.24 expected — a beat of 25.0%.
ANTX does not currently pay a dividend.
Resistance: $41.00, $41.68, $42.68.
Insider activity: SELLING, 1 buys and 4 sells in the last 90 days.
Nov 10, 2026: AN2 Therapeutics Posts Q3 2026 Results · Nov 9, 2026: AN2 Therapeutics reports Q3 EPS of $(0.17), beating $(0.20) estimate · Nov 9, 2026: AN2 Therapeutics, Inc. filed a report on a major company event (Form 8-K)